ANDA 202923, held by Usv. Zoledronic Acid.
As of Nov 14, 2026, ANDA 202923 (Zoledronic Acid), held by Usv, was first approved by FDA on Sep 4, 2014, with 5 approved supplements and 0 published complete response letters.
Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Limitations of Use: The safety and efficacy of zoledronic acid injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 4, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zoledronic AcidEQ 4MG BASE/5ML · injectable;intravenous | Zoledronic Acid | Rx |
| May 19, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 19, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 1, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 11, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 11, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 4, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
